Sartorius Stedim stock: UBS keeps EUR 260.00 target for Sartorius Stedim stock
Published on 10/19/2026 at 15:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- UBS retained its EUR 260.00 target for Sartorius Stedim on October 14, 2026.
- Sartorius Stedim will present its nine-month results on October 22, 2026.
- Sartorius Stedim stock costs EUR 213.00 at Lang & Schwarz on October 19, 2026 at 3:31 p.m. CEST, down 1.21 percent on Euronext Paris.
- The stock trades at a P/E ratio of 70.33 as of October 19, 2026.
UBS retained a Buy rating and a EUR 260.00 price target for Sartorius Stedim on October 14, 2026. The target lies 22.07 percent above the EUR 213.00 Lang & Schwarz price. Sartorius Stedim stock was trading at EUR 213.00 at Lang & Schwarz on October 19, 2026 at 3:31 p.m. CEST, down 1.21 percent on Euronext Paris.
Results arrive on October 22
The next scheduled event is the companys nine-month results, due on October 22, 2026, according to the Sartorius Stedim investor-relations page. That date gives the current analyst target a near-term test, particularly because UBS cited the companys underlying growth path and tariff exposure in its assessment.
Trading range stays near the high
On Euronext Paris, the stock ranged from EUR 212.40 to EUR 217.00 on October 19, 2026. The Lang & Schwarz bid was EUR 212.80 and the ask was EUR 213.20 at 3:31 p.m. CEST. Trading volume on the home listing was 30,656 shares against an average volume of 90,658 shares.
The 52-week range was EUR 150.00 to EUR 225.00 as of October 19, 2026. At EUR 213.00, the stock stood 5.33 percent below the 52-week high. The market capitalization was EUR 20.7 billion, giving the share a substantial valuation premium to the two comparison companies listed below.
Valuation and market comparison
The P/E ratio was 70.33 and the trailing dividend yield was 0.00 percent as of October 19, 2026. UBSs EUR 260.00 target therefore remains the clearest dated valuation reference in the current setup. The company operates in healthcare and supplies instruments, consumables and services to the biopharmaceutical industry.
Comparison with peers
Sartorius Stedim: minus 1.21 percent, P/E 70.33, market capitalization EUR 20.7 billion
Merck KGaA (Xetra, EUR): minus 1.14 percent, P/E 26.17, market capitalization EUR 62.0 billion
Danaher (NYSE, USD): minus 0.03 percent, P/E 40.85, market capitalization USD 161.0 billion
Next marker for the stock
The October 22, 2026 results date is the next scheduled marker for Sartorius Stedim. Investors will be able to compare the companys reported growth with the expectations embedded in the UBS target and the current P/E ratio.
The further course of trading is shown by the continuously updated real-time quote of Sartorius Stedim stock.
Sartorius Stedim market facts
- Company: Sartorius Stedim Biotech S.A.
- ISIN: FR0013154002
- Ticker: DIM
- Primary exchange: Euronext Paris
- Price Lang & Schwarz (as of October 19, 2026, 3:31 p.m. CEST): EUR 213.00
- Change on Euronext Paris: minus 1.21 percent
- Market capitalization: EUR 20.7 billion (as of October 19, 2026)
- 52-week range: EUR 150.00-225.00 (as of October 19, 2026)
- Sector / Industry: Healthcare / Medical Instruments and Supplies
- Index membership: CAC Next 20
- Next earnings date: October 22, 2026
Market context: Market report CAC 40.
